-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although the proportion of patients with locally advanced nasopharyngeal carcinoma who have received standard treatment (such as final concurrent radiochemotherapy with or without induction chemotherapy) is very high, the risk of disease recurrence is still high
Although the proportion of patients with locally advanced nasopharyngeal carcinoma who have achieved complete clinical remission after receiving standard treatment is high, the risk of disease recurrence is still high
This is a multi-center, open-label, parallel-group, randomized controlled Phase 3 trial conducted in 14 hospitals in China.
Receive oral capecitabine rhythm chemotherapy or follow-up observation
From January 25, 2017 to October 25, 2018, a total of 675 patients were screened , of which 406 were recruited and randomly assigned to capecitabine group (n=204) or standard treatment group (n=202) )
Screening
A) survival rate without treatment failure; B) overall survival rate; C) survival rate without remote failure; D) survival rate without local failure
A) survival rate without treatment failure; B) overall survival rate; C) survival rate without remote failure; D) survival rate without local failureAfter a median follow-up of 28 months (range 33-42), 29 relapses or deaths occurred in the capecitabine group (14%), while 53 cases (26%) occurred in the standard treatment group
After a median follow-up of 28 months (range 33-42), 29 relapses or deaths occurred in the capecitabine group (14%), while 53 cases (26%) occurred in the standard treatment group
Adverse events
Adverse events35 cases (17%) of grade 3 adverse events were reported in the capecitabine group, and 11 cases (6%) were reported in the standard treatment group
The study showed that the addition of beat-assisted capecitabine to radiotherapy and chemotherapy significantly improved the treatment failure-free survival rate of high-risk locally advanced nasopharyngeal carcinoma patients, and the safety was controllable
The addition of beat-assisted capecitabine to radiotherapy and chemotherapy significantly improves the treatment failure-free survival rate of high-risk locally advanced nasopharyngeal carcinoma patients, and the safety is controllable
Original source:
Original source:Yu-Pei Chen, et al.
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
in this message
